PMID: 6982586Sep 1, 1982Paper

Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants

Acta Neurologica Scandinavica
L Tjellesen, C Christiansen

Abstract

The serum concentrations of the vitamin D metabolites 25-hydroxyvitamin D (25OHD), 24,25-dihydroxyvitamin D (24,25(OH)2D), and 1,25-dihydroxyvitamin D (1,25(OH)2D) were measured in 18 epileptic patients and 10 controls. The patients were divided according to the anti-convulsant treatment they had been receiving for at least 1 year: 9 patients had received phenytoin and 9 patients carbamazepine, as the sole anti-convulsant therapy. The serum 25OHD was decreased in the patients on phenytoin (P less than 0.01), whereas the other serum vitamin D metabolites were normal. Moreover, serum alkaline phosphatase was increased (P less than 0.001) and serum calcium was decreased (P less than 0.001) in this patient group. In the patient group treated with carbamazepine (a negligible, liver inductor), changes in serum 25OHD and serum alkaline phosphatase were less pronounced (P less than 0.05), but the same degree of hypocalcaemia (P less than 0.001) was present. Our data suggest that liver induction in epileptic patients on anti-convulsant drugs cannot explain the pathophysiology behind anti-convulsant osteomalacia.

References

May 17, 1975·British Medical Journal·C ChristiansenO Munck
Jan 1, 1976·Annual Review of Biochemistry·H F DeLuca, H K Schnoes
Jul 15, 1979·The Biochemical Journal·R M ShepardH F DeLuca
Apr 1, 1977·The Journal of Clinical Endocrinology and Metabolism·W JubizK G Tolman
Jul 9, 1975·Clinica Chimica Acta; International Journal of Clinical Chemistry·C ChristiansenB Petersen
Apr 1, 1973·Physiological Reviews·J L Omdahl, H F DeLuca
Oct 10, 1970·British Medical Journal·C E DentT C Stamp
Oct 10, 1970·British Medical Journal·A Richens, D J Rowe
Jan 16, 1982·British Medical Journal·L TjellesenC Christiansen
Nov 1, 1980·Acta Neurologica Scandinavica·J A O'HareN Callaghan

❮ Previous
Next ❯

Citations

Feb 17, 2000·The Annals of Pharmacotherapy·Y KaraaslanM Oztürk
Mar 20, 2002·Pharmacotherapy·Thomas E Lackner
Aug 17, 2004·Epilepsy Currents·Alison M. Pack
Mar 6, 2010·Expert Opinion on Drug Safety·Karl O Nakken, Erik Taubøll
Sep 26, 2013·The International Journal of Neuroscience·András HollóPéter Lakatos
Jan 1, 1983·Acta Neurologica Scandinavica. Supplementum·T Keränen, J Sivenius
Jul 1, 1983·Acta Neurologica Scandinavica·L TjellesenC Christiansen
Sep 24, 2005·Fundamental & Clinical Pharmacology·M Strolin BenedettiE Baltes
Aug 26, 2009·Epilepsia·Scott Mintzer, Richard T Mattson
Feb 4, 2010·Current Opinion in Neurology·Scott Mintzer
Jan 12, 2013·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Kim RobienJill M Hamilton-Reeves
Mar 1, 1986·Alcohol·D Butler, F S Messiha
Aug 24, 2021·Risk Management and Healthcare Policy·Michael Wakeman
Nov 17, 2009·Clinical Neurology and Neurosurgery·Alberto VerrottiFrancesco Chiarelli
Oct 12, 2010·Pediatric Neurology·Abhijit MisraSangeeta Sharma

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.